FibroGen To Pay SEC $1.25M Over Drug Mistatements
By Katryna Perera · September 8, 2025, 5:52 PM EDT
Biopharmaceutical company FibroGen Inc. has agreed to pay a $1.25 million penalty to the U.S. Securities and Exchange Commission to resolve claims that its former chief medical officer fudged results for...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login